最新ニュース Celularity (NASDAQ:CELU) 株価情報

Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Celularity Inc

Airbnb Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) reported third-quarter financial results Thursday after the bell. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/n41823683/airbnb-announces-third-quarter-2024-results">rundown of the report</a>.
Q3 Earnings: Airbnb reported third-quarter revenue of $3.70 billion, missing the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $3.72 billion. The company reported third-quarter earnings of $2.13 per share, missing analyst estimates of $2.16 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 10% year-over-year. Gross booking value totaled $20.1 billion, up 10% year-over-year. Nights and Experiences booked came in at $122.8 million, up 8% year-over-year.
Airbnb said it generated $1.1 billion of free cash flow during the quarter. The company ended the quarter with $11.3 billion in cash, cash equivalents, short-term investments and&nbsp;restricted cash.
&#8220;Airbnb had a strong Q3. Nights and Experiences Booked accelerated throughout the quarter and into Q4, despite a softer start due to shorter booking lead times compared to 2023,&#8221; the company said in a letter to shareholders.
&#8220;Building on robust momentum in September, we are off to a great start in fourth quarter 2024. We are seeing strong demand trends in Q4 2024 across core and expansion markets for both long and short lead times.&#8221;
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820744/9-stocks-to-watch-financial-sector-outshines-tech-in-2024-as-trump-trade-sparks-m-a">9 Stocks To Watch: Financial Sector Outshines Tech In 2024 As &#8216;Trump Trade&#8217; Sparks M&amp;A Optimism</a>
Outlook:&nbsp;Airbnb expects fourth-quarter revenue to be in the range of $2.39 billion to $2.44 billion. The company expects Nights and Experiences booked in the fourth quarter to be higher than in the third quarter. 
Airbnb anticipates full-year 2024 adjusted EBITDA margin of approximately 35.5% The company expects full-year free cash margin to be &#8220;several points above&#8221; adjusted EBITDA margins.
Airbnb executives will discuss the company&#8217;s quarterly results on a call with analysts and investors at 4:30 p.m. ET.
ABNB Price Action: <a href="https://www.benzinga.com/quote/ABNB" target="_blank" rel="noreferrer noopener">Airbnb shares</a> were down 2.08% in after-hours, trading at $142.50 at the time of publication Thursday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41820253/fed-cuts-interest-rates-to-lowest-since-february-2023-sticks-to-data-driven-path"> • Fed Cuts Interest Rates To Lowest Since February 2023, Sticks To Data-Driven Path (CORRECTED)</a>
Photo: Shutterstock.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Airbnb Q3 2024 Earnings Call &#x7C; $ABNB" width="500" height="281" src="https://www.youtube.com/embed/RR_D086agzA?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Earnings

News

Travel

After-Hours Center

Movers

General

ABNB

Airbnb Stock Down On Q3 Earnings: 'Building On Robust Momentum In September, We Are Off To A Great Start In Q4'

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) reported quarterly earnings of $1.61 per share which beat the analyst consensus estimate of $1.59 by 1.26 percent. This is a 20.15 percent increase over earnings of $1.34 per share from the same period last year. The company reported quarterly sales of $159.30 million which beat the analyst consensus estimate of $155.57 million by 2.40 percent. This is a 16.53 percent increase over sales of $136.71 million the same period last year.

Earnings Beats

COLL

Collegium Pharmaceutical Q3 Adj $1.61 Beats $1.59 Estimate, Sales $159.30M Beat $155.57M Estimate

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) affirms FY2024 sales outlook from $140.00 million-145.00 million to $140.00 million-145.00 million.

Guidance

CUTR

Cutera Affirms FY2024 Sales Guidance to $140.00M-145.00M  VS Est.141.53M

Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) lowers FY2024 sales outlook from $450.00 million-470.00 million to $440.00 million-455.00 million.

PRCH

Porch Group Lowers FY2024 Sales Guidance from $450.00M-470.00M to $440.00M-455.00M

BILL

BILL Holding Sees FY25 Adj. EPS $1.65-$1.83 Vs $1.55 Est.; $1.439B-$1.464B Vs $1.437B

Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) reported $354.41 thousand in sales this quarter. This is a 115.91 percent increase over sales of $164.15 thousand the same period last year.

REFR

Research Frontiers Q3 Sales $354.41K Up From $164.15K YoY

BILL Holding Sees Q2 Adj. EPS $0.44-$0.48; Revenue $355.5M-$360.5M

ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.14 by 142.86 percent. The company reported quarterly sales of $285.25 million which missed the analyst consensus estimate of $316.34 million by 9.83 percent. This is a 17.67 percent increase over sales of $242.42 million the same period last year.

Earnings Misses

ProAssurance Q3 2024 Adj EPS $0.34 Beats $0.14 Estimate, Sales $285.25M Miss $316.34M Estimate

Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) affirms FY2024 sales outlook from $410.00 million-425.00 million to $410.00 million-425.00 million.

BRLT

Brilliant Earth Group Affirms FY2024 Sales Guidance from $410.00M-425.00M to $410.00M-425.00M

Mettler-Toledo Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) reported quarterly earnings of $10.21 per share which beat the analyst consensus estimate of $10.01 by 2 percent. The company reported quarterly sales of $954.53 million which beat the analyst consensus estimate of $944.74 million by 1.04 percent. This is a 1.28 percent increase over sales of $942.46 million the same period last year.

Mettler-Toledo Intl Q3 2024 Adj EPS $10.21 Beats $10.01 Estimate, Sales $954.53M Beat $944.74M Estimate

Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) affirms FY2024 Adj EPS guidance from $5.45-5.55 to $5.45-5.55 vs $5.50 analyst estimate. Narrows FY2024 sales outlook from $338.00 million-353.00 million to $346.00 million-350.00 million vs $344.10 million estimate.

CCSI

Consensus Cloud Solns Affirms FY2024 Adj EPS Guidance from $5.45-5.55 to $5.45-5.55 vs $5.50 Est; Narrows FY2024 Sales Guidance from $338.00M-353.00M to $346.00M-350.00M vs $344.10M Est

Outlook2
For the fourth quarter ending December 31, 2024, Toast expects to report:
<ul>
<li>Non-GAAP subscription services and financial technology solutions gross profit in the range of $370 million to $380 million (32-35% growth compared to Q4 2023)</li>
<li>Adjusted EBITDA in the range of $90 million to $100 million</li>
</ul>
For the full year ending December 31, 2024, Toast expects to report:
<ul>
<li>Non-GAAP subscription services and financial technology solutions gross profit in the range of $1,395 million to $1,405 million (32-33% growth compared to 2023, up from 27-29% growth)</li>
<li>Adjusted EBITDA in the range of $352 million to $362 million (up from $285 million to $305 million)</li>
</ul>
The outlook provided above constitutes forward-looking information within the meaning of applicable securities laws and is based on a number of assumptions and subject to a number of risks. See cautionary note regarding "Forward-looking Statements" in this press release.

TOST

Toast Sees Q4 Non-GAAP Subscription Services And Financial Technology Solutions Gross Profit In The Range Of $370M-$380M; FY24 Non-GAAP Subscription Services And Financial Technology Solutions Gross Profit In The Range Of $1.395B-$1.405B

Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent.

ALLO

Allogene Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate

Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 33.33 percent. This is a 20 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $286.87 million which beat the analyst consensus estimate of $282.56 million by 1.52 percent. This is a 4.16 percent increase over sales of $275.40 million the same period last year.

GTBIF

Green Thumb Industries Q3 EPS $0.04 Misses $0.06 Estimate, Sales $286.87M Beat $282.56M Estimate

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) lowers FY2024 Adj EPS guidance from $5.13-5.20 to $1.15-1.19 vs $1.29 analyst estimate. Lowers FY2024 sales outlook from $944.00 million-950.00 million to $939.00 million-943.00 million vs $946.02 million estimate.

NVEE

NV5 Global provides FY2024 guidance: Gross revenues $939M-$943M (est. 946.02M); GAAP EPS $0.48-$0.54 (est. 0.67); Adj. EPS $1.15-$1.19 (adjusted for 4-1 stock split) vs (est. 1.29)

Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) is looking for Q4 Adj EPS of $1.14-1.24 vs $1.21 analyst estimate. sees sales of $83.000 million-87.000 million vs $83.26 million estimate.

Consensus Cloud Solns Sees Q4 Adj EPS $1.14-1.24 vs $1.21 Est; Sees Sales $83.000M-87.000M vs $83.26M Est

SENS

Senseonics Sees FY24 Revenue $22M Vs $22.182M Est.

DXC Technology Sees Q3 2025 Revenue $3.2B-$3.3B Vs $3.2B Est.; Sees Adj EPS $0.75-$0.80 Vs $0.72 Est.

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $1.965 million which missed the analyst consensus estimate of $5.420 million by 63.74 percent. This is a 56.60 percent decrease over sales of $4.528 million the same period last year.

GEVO

Gevo Q3 2024 GAAP EPS $(0.09) Misses $(0.07) Estimate, Sales $1.965M Miss $5.420M Estimate

SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported $10.00 million in sales this quarter. This is a 8.28 percent increase over sales of $9.23 million the same period last year.

SIGA

SIGA Technologies Q3 EPS $0.02 Up From $(0.01) YoY, Sales $10.00M Up From $9.23M YoY

Celularity receives Nasdaq notice regarding late Form 10-K filing

Catalyst Watch: AI in the spotlight with Nvidia earnings, Microsoft Build, and an IBM event

Celularity announces receipt of Nasdaq notice regarding late Form 10-Q filing

Celularity (CELU) has shared an update. Marc Mazur, a key board member of Celularity, has announced his resignation, effective July 31, 2024. His d...

Celularity Board Member Marc Mazur Announces Resignation

Celularity receives Nasdaq notice regarding late Form 10-Q filing

The latest announcement is out from Celularity (CELU). Celularity Inc. has announced the appointment of Richard J. Berman as a Class II director, f...

Celularity Announces Board Changes and New Indemnification Agreement

Celularity acquires Rebound product from Sequence Lifescience

Celularity receives Nasdaq notice, intends to file appeal

Celularity (CELU) issued a Corporate Update to Shareholders from Robert Hariri, Founder, Chairman, and CEO, which read in part, "Let me start by re...

Celularity to submit 510(k) notification for Tendon Wrap in early 2025

Celularity (CELU) has requested a hearing before the Nasdaq Hearings Panel the Nasdaq Listing Qualifications Department's determination regarding C...

Celularity files amended compliance plan with Nasdaq Hearings Panel

AAUKF

BYDDF

CELU

CELUW

DELL

DTRUY

MSFT

NGLOY

NKLA

NVDA

PANW

RIVN

SUPN

TMUS

TSLA

Press Releases

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Management

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Markets

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Provides Corporate Update

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Aligos Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Elevation Oncology

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Fresh2 Group Limited - American Depositary Shares

Fresh2 Group

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

ImmuCell

MiNK Therapeutics

Longeveron

Lantern Pharma

Lumos Pharma

Marker Therapeutics

NextCure

Ocean Biomedical

SAB Biotherapeutics

Surrozen

vTv Therapeutics Inc. - Class A Common Stock

Comments

Celularity

ニュース

最新ニュース Celularity (NASDAQ:CELU) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル